Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study

Stefano Luminari, Michele Merli, Sara Rattotti, Vittoria Tarantino, Luigi Marcheselli, Federica Cavallo, Marzia Varettoni, Benedetta Bianchi, Francesco Merli, Alessandra Tedeschi, Giuseppina Cabras, Francesca Re, Carlo Visco, Marcia Torresan Delamain, Emanuele Cencini, Michele Spina, Simone Ferrero, Angela Ferrari, Marina Deodato, Donato ManninaOmbretta Annibali, Angela Rago, Lorella Orsucci, Irene Defrancesco, Marco Frigeni, Marina Cesaretti, Luca Arcaini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Marginal zone lymphomas (MZLs) are indolent nonfollicular B-cell lymphomas (INFLs) and have heterogeneous clinical behavior. Recently, time to progression of disease at 24 months (POD24) was identified to stratify overall survival (OS) in follicular non-Hodgkin lymphoma and in INFL. Here, we examined the ability of POD24 to predict subsequent OS in a large, international cohort of MZL as part of the NF10 prospective international registry headed by Fondazione Italiana Linfomi (FIL). POD24 was only calculated for MZL patients requiring immediate therapy and was defined as experiencing lymphoma progression within 24 months from diagnosis. Among the 1325 patients enrolled in the NF10 study, we identified 321 patients with MZL for whom immediate therapy was planned right after lymphoma diagnosis. Overall, POD24 was confirmed in 59 patients (18%). Three-year OS for patients with POD24 was 53% with a hazard ratio of 19.5 (95% confidence interval, 8.4-45) compared with patients without POD24 (3-year OS, 95%). Association of POD24 with OS was confirmed for the subgroup of splenic and extranodal MZLs. Assessment of POD24 stratifies subsequent outcome in MZL and identifies a high-risk population. This trial was registered at www.clinicaltrials.gov as #NCT02904577.

Original languageEnglish
Pages (from-to)798-801
Number of pages4
JournalBlood
Volume134
Issue number10
DOIs
Publication statusPublished - Sep 5 2019

Fingerprint

Disease Progression
Lymphoma
Survival
B-Cell Lymphoma
Follicular Lymphoma
Non-Hodgkin's Lymphoma
Registries
Hazards
Cells
Confidence Intervals
Therapeutics
Population

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Early progression as a predictor of survival in marginal zone lymphomas : an analysis from the FIL-NF10 study. / Luminari, Stefano; Merli, Michele; Rattotti, Sara; Tarantino, Vittoria; Marcheselli, Luigi; Cavallo, Federica; Varettoni, Marzia; Bianchi, Benedetta; Merli, Francesco; Tedeschi, Alessandra; Cabras, Giuseppina; Re, Francesca; Visco, Carlo; Torresan Delamain, Marcia; Cencini, Emanuele; Spina, Michele; Ferrero, Simone; Ferrari, Angela; Deodato, Marina; Mannina, Donato; Annibali, Ombretta; Rago, Angela; Orsucci, Lorella; Defrancesco, Irene; Frigeni, Marco; Cesaretti, Marina; Arcaini, Luca.

In: Blood, Vol. 134, No. 10, 05.09.2019, p. 798-801.

Research output: Contribution to journalArticle

Luminari, S, Merli, M, Rattotti, S, Tarantino, V, Marcheselli, L, Cavallo, F, Varettoni, M, Bianchi, B, Merli, F, Tedeschi, A, Cabras, G, Re, F, Visco, C, Torresan Delamain, M, Cencini, E, Spina, M, Ferrero, S, Ferrari, A, Deodato, M, Mannina, D, Annibali, O, Rago, A, Orsucci, L, Defrancesco, I, Frigeni, M, Cesaretti, M & Arcaini, L 2019, 'Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study', Blood, vol. 134, no. 10, pp. 798-801. https://doi.org/10.1182/blood.2019001088
Luminari, Stefano ; Merli, Michele ; Rattotti, Sara ; Tarantino, Vittoria ; Marcheselli, Luigi ; Cavallo, Federica ; Varettoni, Marzia ; Bianchi, Benedetta ; Merli, Francesco ; Tedeschi, Alessandra ; Cabras, Giuseppina ; Re, Francesca ; Visco, Carlo ; Torresan Delamain, Marcia ; Cencini, Emanuele ; Spina, Michele ; Ferrero, Simone ; Ferrari, Angela ; Deodato, Marina ; Mannina, Donato ; Annibali, Ombretta ; Rago, Angela ; Orsucci, Lorella ; Defrancesco, Irene ; Frigeni, Marco ; Cesaretti, Marina ; Arcaini, Luca. / Early progression as a predictor of survival in marginal zone lymphomas : an analysis from the FIL-NF10 study. In: Blood. 2019 ; Vol. 134, No. 10. pp. 798-801.
@article{a9c0f041353241d6bc3faef06e537649,
title = "Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study",
abstract = "Marginal zone lymphomas (MZLs) are indolent nonfollicular B-cell lymphomas (INFLs) and have heterogeneous clinical behavior. Recently, time to progression of disease at 24 months (POD24) was identified to stratify overall survival (OS) in follicular non-Hodgkin lymphoma and in INFL. Here, we examined the ability of POD24 to predict subsequent OS in a large, international cohort of MZL as part of the NF10 prospective international registry headed by Fondazione Italiana Linfomi (FIL). POD24 was only calculated for MZL patients requiring immediate therapy and was defined as experiencing lymphoma progression within 24 months from diagnosis. Among the 1325 patients enrolled in the NF10 study, we identified 321 patients with MZL for whom immediate therapy was planned right after lymphoma diagnosis. Overall, POD24 was confirmed in 59 patients (18{\%}). Three-year OS for patients with POD24 was 53{\%} with a hazard ratio of 19.5 (95{\%} confidence interval, 8.4-45) compared with patients without POD24 (3-year OS, 95{\%}). Association of POD24 with OS was confirmed for the subgroup of splenic and extranodal MZLs. Assessment of POD24 stratifies subsequent outcome in MZL and identifies a high-risk population. This trial was registered at www.clinicaltrials.gov as #NCT02904577.",
author = "Stefano Luminari and Michele Merli and Sara Rattotti and Vittoria Tarantino and Luigi Marcheselli and Federica Cavallo and Marzia Varettoni and Benedetta Bianchi and Francesco Merli and Alessandra Tedeschi and Giuseppina Cabras and Francesca Re and Carlo Visco and {Torresan Delamain}, Marcia and Emanuele Cencini and Michele Spina and Simone Ferrero and Angela Ferrari and Marina Deodato and Donato Mannina and Ombretta Annibali and Angela Rago and Lorella Orsucci and Irene Defrancesco and Marco Frigeni and Marina Cesaretti and Luca Arcaini",
year = "2019",
month = "9",
day = "5",
doi = "10.1182/blood.2019001088",
language = "English",
volume = "134",
pages = "798--801",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Early progression as a predictor of survival in marginal zone lymphomas

T2 - an analysis from the FIL-NF10 study

AU - Luminari, Stefano

AU - Merli, Michele

AU - Rattotti, Sara

AU - Tarantino, Vittoria

AU - Marcheselli, Luigi

AU - Cavallo, Federica

AU - Varettoni, Marzia

AU - Bianchi, Benedetta

AU - Merli, Francesco

AU - Tedeschi, Alessandra

AU - Cabras, Giuseppina

AU - Re, Francesca

AU - Visco, Carlo

AU - Torresan Delamain, Marcia

AU - Cencini, Emanuele

AU - Spina, Michele

AU - Ferrero, Simone

AU - Ferrari, Angela

AU - Deodato, Marina

AU - Mannina, Donato

AU - Annibali, Ombretta

AU - Rago, Angela

AU - Orsucci, Lorella

AU - Defrancesco, Irene

AU - Frigeni, Marco

AU - Cesaretti, Marina

AU - Arcaini, Luca

PY - 2019/9/5

Y1 - 2019/9/5

N2 - Marginal zone lymphomas (MZLs) are indolent nonfollicular B-cell lymphomas (INFLs) and have heterogeneous clinical behavior. Recently, time to progression of disease at 24 months (POD24) was identified to stratify overall survival (OS) in follicular non-Hodgkin lymphoma and in INFL. Here, we examined the ability of POD24 to predict subsequent OS in a large, international cohort of MZL as part of the NF10 prospective international registry headed by Fondazione Italiana Linfomi (FIL). POD24 was only calculated for MZL patients requiring immediate therapy and was defined as experiencing lymphoma progression within 24 months from diagnosis. Among the 1325 patients enrolled in the NF10 study, we identified 321 patients with MZL for whom immediate therapy was planned right after lymphoma diagnosis. Overall, POD24 was confirmed in 59 patients (18%). Three-year OS for patients with POD24 was 53% with a hazard ratio of 19.5 (95% confidence interval, 8.4-45) compared with patients without POD24 (3-year OS, 95%). Association of POD24 with OS was confirmed for the subgroup of splenic and extranodal MZLs. Assessment of POD24 stratifies subsequent outcome in MZL and identifies a high-risk population. This trial was registered at www.clinicaltrials.gov as #NCT02904577.

AB - Marginal zone lymphomas (MZLs) are indolent nonfollicular B-cell lymphomas (INFLs) and have heterogeneous clinical behavior. Recently, time to progression of disease at 24 months (POD24) was identified to stratify overall survival (OS) in follicular non-Hodgkin lymphoma and in INFL. Here, we examined the ability of POD24 to predict subsequent OS in a large, international cohort of MZL as part of the NF10 prospective international registry headed by Fondazione Italiana Linfomi (FIL). POD24 was only calculated for MZL patients requiring immediate therapy and was defined as experiencing lymphoma progression within 24 months from diagnosis. Among the 1325 patients enrolled in the NF10 study, we identified 321 patients with MZL for whom immediate therapy was planned right after lymphoma diagnosis. Overall, POD24 was confirmed in 59 patients (18%). Three-year OS for patients with POD24 was 53% with a hazard ratio of 19.5 (95% confidence interval, 8.4-45) compared with patients without POD24 (3-year OS, 95%). Association of POD24 with OS was confirmed for the subgroup of splenic and extranodal MZLs. Assessment of POD24 stratifies subsequent outcome in MZL and identifies a high-risk population. This trial was registered at www.clinicaltrials.gov as #NCT02904577.

UR - http://www.scopus.com/inward/record.url?scp=85071786735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071786735&partnerID=8YFLogxK

U2 - 10.1182/blood.2019001088

DO - 10.1182/blood.2019001088

M3 - Article

C2 - 31292118

AN - SCOPUS:85071786735

VL - 134

SP - 798

EP - 801

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -